Multiple myeloma – Drug Pipeline Analysis and Market Forecasts to 2016
01/06/2010

The Multiple Myeloma Market Is In High Growth Trajectory Mode That Is Expected To Mature By 2016.

Online PR News – 06-January-2010 – – The global multiple myeloma market was valued at $1,818.3m in 2009 and is forecast to grow at a CAGR of 5.2% for the next seven years to reach $2600m by 2016. The growth will primarily be driven by an increase in the disease incidence rate, an increase in awareness of the treatment options, an increase in the treatment seeking population, and the acceptance of the existing therapies.
Globally, the US remains the largest multiple myeloma disease market, and is forecast to grow at a CAGR of 5.2% over the next seven years until 2016. The most of the demand was estimated to coming from the developed economies.

For further details please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Multiple-Myeloma-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Celgene Corporation, BMS, GSK, and millennium Pharmaceutical remain the leading competitors in the global multiple myeloma market. The competitive landscape is strong with five approved therapies. The market remains highly consolidated with very few players dominating the multiple myeloma market space.

More than 145 products were in different developmental stages in 2009, PegIntron, Tanespimycin and SRT-501-012 are the key products currently in the pipeline. The emergences of combinational therapies are expected to intensify the competition. The pipeline has 61 combinational therapies that being studied in the various stages of the pipeline. The first in class drugs have no vaccine or path breaking drugs.

For further details please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Multiple-Myeloma-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

The current multiple myeloma market is highly competitive with five approved therapies. The existing therapies have increased the overall survival rate significantly over the past 15 years. Though the disease is not curable the current treatment options provide the patient population with better efficacy. The increase in overall survival rate has, signified the translation of multiple myeloma to a chronic condition.

GlobalData, the industry analysis specialist, has released its latest research “Multiple myeloma - Drug Pipeline Analysis and Market Forecasts to 2016” that provides key data, information and analysis on the global multiple myeloma disease market. The report provides a comprehensive overview on the annualized market data from 2000 to 2008, and forecasts forward seven years to 2015. The report provides coverage of the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need or commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among pipeline molecules, as well as an insight into the most promising pipeline drugs supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for future market competition is also outlines.

For further details please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Multiple-Myeloma-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore